Scientific Advisory Board

  • Alan Wright, MD MPH

    Alan Wright, MD MPH is the Head of Medical Affairs for bioMerieux and serves as a key clinical and policy spokesperson for the company in the field of diagnostic medicine. Dr. Wright previously served as the Chief Medical Officer and Chief Science Officer at Roche Diagnostics Corporation.

    With extensive experience in managed care, pharmaceuticals, clinical labs, and biotechnology, Dr. Wright has deep expertise in regulatory, payer policy, and legislative issues.

  • Peter Pronovost, MD PhD

    Peter Pronovost, MD PhD, is a world-renowned critical care physician, patient safety champion, and thought leader in U.S. and global health policy. He currently serves as the Head of Clinical Transformation for University Hospitals, previously holding positions as the VP of Patient Safety & Quality at Johns Hopkins Medicine and the SVP Clinical Strategy & Chief Medical Officer at United Healthcare. Dr. Pronovost is a prolific researcher and is widely recognized for his transformative work leveraging checklists to reduce central line-associated bloodstream infections by 80%, earning him a MacArthur Foundation "Genius Grant". He also serves as a member of President Biden's Council of Advisors on Science and Technology (PCAST).

  • Samuel Herschkowitz, MD

    Samuel Herschkowitz, MD is a distinguished executive with over 40 years of experience in biotechnology, medical devices, and pharmaceutical development. He is a board-certified neurologist and psychiatrist who has founded multiple healthcare companies and held high-level management and governance positions in both public and private entities. Dr. Herschkowitz has also successfully managed multiple healthcare and biotech funds with impressive YoY returns exceeding 30%. Additionally, he is the founder of Medtech Associates, a leading consulting firm that specializes in conducting comprehensive due diligence investigations for healthcare investors.

  • Rich Macary

    Rich Macary is the President of Macary Advisors, LLC, a Biotech/MedTech consulting and advisory firm that assists institutional and high net worth investors, as well as public and private companies. He previously served as the Chief Strategy Officer and President of Delos Ventures, where he helped launch the Well Living Lab, a collaboration with Mayo Clinic. Rich has also held executive positions at Sarepta Therapeutics, a leader in rare and infectious disease therapies. He is a thought leader in the industry and has been featured in Forbes, The Wall Street Journal, Wired, CNN, Barron's, Reuters, Bloomberg and other publications.

  • Chad Beyer, PhD MBA

    Chad Beyer, PhD MBA, is a seasoned leader with 25 years of experience in discovering, researching, and developing novel disease-modifying medications. As the CEO of Kures, an Atai Life Sciences company, Chad is dedicated to developing treatment options for addiction, depression, and pain. Prior to Kures, he served as the Senior Vice President of R&D at Promentis Pharmaceuticals, where he led several preclinical and clinical drug discovery teams and participated in the submission of over 30 INDs. Chad also played a key role in the development of two blockbuster medications: Effexor® and Pristiq®. In addition to his extensive industry experience, he serves as a scientific advisor to the Michael J. Fox Foundation for Parkinson's Research.

  • Michael P. Aquino, MD

    Michael P. Aquino, MD is a pioneering healthcare executive, physician, advisor, and investor with decades of experience in various biotech companies. He founded A2Z Diagnostics, which became the largest anatomic pathology lab in the United States before being acquired by Aurora Diagnostics. Currently, he serves as the COO of another full-scale anatomic and molecular pathology lab. Additionally, he is the Chairman of the NJ Governor’s Council for Medical Research and Treatment of Autism, demonstrating his commitment to advancing healthcare through research and advocacy.

NeuBio Leadership Team

  • Marley Bankoff

    CO-FOUNDER & CEO

  • Molly Scofield

    CO-FOUNDER & COO

  • Patrick Lilley

    CO-FOUNDER, BOARD MEMBER

  • Ian Manger PhD

    DIAGNOSTICS & RESEARCH

  • Jonathan Zamir

    CO-FOUNDER, FINANCE DIRECTOR

  • Daniel Davis

    CO-FOUNDER, VP OF PARTNERSHIPS

  • John Ballantine

    CO-FOUNDER, CORPORATE RELATIONS

  • Andrew Creighton

    PATIENT REPRESENTATIVE

  • CEO

    Marley Bankoff is an interdisciplinary entrepreneur with a decade of experience in developing disruptive technologies that improve human health. Marley has founded and built multiple organizations and technologies across a variety of bio-related industries and emerging markets, focusing on pioneering manufacturing processes and drug delivery systems. Marley's passion for solving big problems has driven the development of innovative solutions that have the potential to transform the way drugs are manufactured and delivered, with a focus on improving human health outcomes.

  • COO

    Molly Scofield is the COO and co-founder of NeuBio. With over 20 years of experience in operations and digital technology, she has worked closely with Fortune 100 companies to develop solutions through some of the biggest tech advancements in various industries, including smartphones, search engines, e-commerce, and social media. Since 2016, Molly has led projects almost exclusively in life sciences and healthcare. Her strong data analytics and technology competency has been honed through her work as an embedded resource for early-stage pharma and medical device companies. Molly's extensive experience in life sciences and healthcare, combined with her technological expertise, uniquely qualify her to lead NeuBio. She is passionate about leveraging the latest advancements to improve patient outcomes and drive innovation in the healthcare industry.

  • Patrick Lilley brings over 25 years of experience in driving innovation and growth in biotech, software, high-performance computing, and wireless. He has co-founded 4 technology startups and 4 life sciences companies, and discovered hundreds of novel biomarkers for 28 diseases. Lilley has also been the inventor of 75 technology patents and trade secrets in bioinformatics, tissue sample quality control, high-performance algorithms, security, and wireless. In addition, he is a member of the MDEpiNet Blockchain and Artificial Intelligence Task Force and has been a guest lecturer at top universities including Cal Tech, MIT, Stanford, UC Berkeley, and USC.

  • Head of Diagnostics & R&D

    Ian Manger brings over 25 years of clinical and pre-clinical development to NeuBio. Dr. Manger earned his PhD in Biochemistry from Oxford University and conducted his post-doctoral studies in infectious disease genomics at Stanford University. Dr. Manger has extensive expertise in molecular diagnostic development, with regulatory and IRB protocols and in drug repurposing.

  • Director of Finance

    As Director of Finance, Jonathan Zamir plays a crucial role in decision-making related to deal sourcing, co-investment opportunities, debt financing, and major transactional matters. In addition to overseeing all company activities, Jonathan also manages the day-to-day operations of the firm. Prior to co-founding NeuBio, Jonathan gained extensive experience in real estate, starting his career as a Portfolio Manager for The Moinian Group, a leading RE firm in the nation. Later, he served as the Director of Acquisitions for Infinity Real Estate, where he was responsible for negotiating, structuring, and closing multi-million dollar transactions involving office, multi-family, hotel, and retail assets throughout the United States. These deals were valued at well over $500 million.

  • Vice President of Partnerships and Business Affairs

    As Vice President of Partnerships and Business Affairs at NeuBio, Daniel Davis is an innovative executive with a focus on health. With a background in investment, business development, and creative leadership, he has spent over 10 years advising family offices and corporate clients in the life sciences, media, and technology sectors. Daniel is the co-founder and Managing Partner of Amber Equities, a New York-based investment platform that focuses on consumer brands and technology, with a strong emphasis on health and wellness. He has also held Creative Executive roles at Sony Music Entertainment and Warner Music Group, bringing a unique perspective to NeuBio's approach to innovation in the health industry.

  • Head of Corporate Relations

    John Ballantine has over 20 years of management experience in the computer and internet industries, making him a valuable asset to the company.

    John co-founded Online Interactive, Inc. (OLI) in 1994, where he served as Executive Vice President before becoming its President and CEO. Under his leadership, OLI became the largest reseller in the electronic software distribution market, with licensing agreements with over 250 software publishers and over 3,000 electronic products within three years. In 1997, he successfully sold OLI to MicroWarehouse, Inc. and remained as the President of the Seattle operation and as a Vice President at MicroWarehouse.

    Before the sale of OLI, John led the OLI Senior Management team and the Board of Directors through a corporate restructuring that resulted in the spin-off of a division of OLI called FreeShop.com. He served on the Board of Directors for nine years (1994-2003) and was the Board Chairman of Aptimus (formerly Freeshop), a company that he helped lead to a successful IPO in 1999. In 2007, Aptimus was acquired by the Apollo Group (APOL).

    Prior to his time at OLI, John was the Vice President of Softdisk Publishing from 1991 to 1994, where he pioneered the world's first Electronic Software Download Store and managed online shopping applications with GENIE, Delphi, America Online, CompuServe, and Prodigy.

    John is an accomplished investor in over 30 private companies, making him a valuable resource for NeuBio. His experience and success in the computer and internet industries have prepared him well to help lead NeuBio to success in the health industry.

  • Patient Representative, Board Advisor

    Andrew Creighton joins NeuBio as a patient representative on our Scientific Advisory Board. Mr. Creighton has served on the Michael J. Fox Foundation (MJFF) Board of Directors since 2016. MJFF is the largest non-profit funder of Parkinson’s Research in the world. In addition to his role with MJFF, Mr. Creighton founded Advice/AC in 2018, a think tank to identify opportunities to positively impact global health and sustainability. Prior to his work with MJFF, he was the founder and CEO of Vice Media in Europe where he oversaw the brand’s global expansion, growing the company to over $700M of annual revenue, 3,000 employees and a $5.7B valuation. As a Parkinson’s patient himself, and with his deep experience in digital media and communications, Mr. Creighton is in a unique position to inform our approach to engaging with his community of fellow patients and the foundations that serve them..